FRONTO-TEMPORAL DEMENTIA

Frontotemporal dementia is estimated to account for around 10-15% of all dementia cases in the US, with the majority of patients only surviving an average of 6-8 years after diagnosis. But in a new study, researchers from the University of Alabama at Birmingham say they may have uncovered a potential drug target for the disease.

Researchers found that mutated tau impairs the connections between neurons by reducing the size of anchoring sites for NMDA receptors crucial for brain signaling.
Frontotemporal dementia (FTD) is characterized by rapid deterioration of language skills, movement and changes in personality, behavior and social skills. Onset of FTD most commonly occurs during mid-late 50s - significantly earlier than the average age of Alzheimer's disease onset.

Cycloserine is believe to boost NMDA receptor or the brain responsible for
Signaling